Relation between changes in foveal choroidal thickness and 1-year results of ranibizumab therapy for polypoidal choroidal vasculopathy

Abstract

The subfoveal choroidal thickness decreased during ranibizumab therapy, which was associated with resolved polypoidal lesions and foveal retinal thickness, and may be associated with PCV activity.

Aflibercept therapy in eyes with neovascular age‐related macular degeneration and its effect on choroidal thickness

“…In this study, after aflibercept injections, the SCT in Group 1 reduced from 190.9 ± 56 μm to 168.7 ± 50.6 μm (p = 0.014). This finding is in keeping with the finding of Branchini et al who reported a decrease in choroidal thickness after treatment with other anti‐vascular endothelial growth factor agents (ranibizumab and bevacizumab) and Hikichi et al who reported a significant decrease in choroidal thickness after ranibizumab treatment in eyes with polypoidal choroidal vasculopathy.…”

“…Forty‐eight eyes in Group 1 and 41 eyes in Group 2 were included in the study. Mean follow‐up time was 6.2 ± 1.9 () months in Group 1 and 6.8 ± 2.1 (5–28) months in Group 2. The mean age was 69.6 ± 9.4 (53–90) years in the naive group and 71.9 ± 8.7 (57–86) years in the resistant group.…”

Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: a comparative study

“…In an early report by Yamazaki et al ,8 subfoveal choroidal thickness was significantly decreased after only one ranibizumab injection. Other studies have shown decreased choroidal thickness after anti-VEGF treatment for neovascular AMD14 as well as for PCV 7. However, contradictory data have also been reported.…”

“…It is well-known that eyes with PCV usually exhibit greater choroidal thickness than those with typical neovascular AMD 2. Recently, Hikichi et al 7 showed that the decrease in choroidal thickness after anti-VEGF therapy is closely associated with a decrease in foveal retinal thickness. In addition, the decrease in choroidal thickness was greater in eyes which had exhibited polyp regression than in those which had not.…”

“…Several studies have shown a decrease in choroidal thickness after intravitreal ranibizumab therapy 7 8. Recent reports have also demonstrated a decrease in choroidal thickness after intravitreal injection of a more recently developed anti-VEGF agent: aflibercept 9 10.…”